Global Cardioverter Defibrillator Device market

Cardioverter Defibrillator Device Market Size, Share, Growth Analysis, By Type(implantable cardioverter defibrillators, external cardioverter defibrillators), By End use(hospitals, pre-hospital, public access market, alternative care), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2207 | Region: Global | Published Date: February, 2024
Pages: 224 | Tables: 64 | Figures: 75

Cardioverter Defibrillator Device Market News

  • In June 2020, ZOLL Medical Corporation, an Asahi Kasei Group Company received premarket approval for its ZOLL AED 3 defibrillator with enhanced real CPR help, integrated child rescue, and wireless connectivity.
  • In 2020, the US FDA approved leadless defibrillator for heart patients. This device can be implanted directly into the heart and does not require any non-invasive surgeries.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Cardioverter Defibrillator Device Market was valued at USD 13.79 billion in 2022, and is poised to grow from USD 14.78 billion in 2023, to USD 25.78 Billion by 2031 at a CAGR of 7.20% during the forecast period (2024-2031).

Global cardioverter defibrillator devices market is highly competitive. Implantable cardioverter defibrillator key market players are Medtronic PLC, Abbott Laboratories, and Boston Scientific Corporation. Koninklijke Philips N.V., Cardiac Science Corporation, and Zoll Medical Corporation are leading the external defibrillator market. Key players undergo mergers and acquisitions to produce innovative products. They also focus on strengthening their position in the global market. 'Medtronic PLC', 'Abbott Laboratories', 'Boston Scientific Corporation', 'BIOTRONIK SE & Co. KG', 'LivaNova PLC', 'Stryker Corporation', 'Koninklijke Philip N.V.', 'Cardiac Science Corporation', 'Zoll medical corporation', 'Nihon Kohden Corporation', 'Progetti Srl', 'Fukuda Denshi Co.', 'Schiller AG'

Defibrillators have improved in terms of cost, size reduction, and ease of operation. The advancement in technology is as follows- automated external defibrillator (AED) and implantable cardioverter defibrillator (ICD). These devices are effective in controlling cardiac attack conditions. Due to technological advancements in defibrillators, the operating defibrillator has become easy for an observer post-induction of proper training.

Smart Pacemaker to Elevate Market Demand: Smart pacemaker is a device that can detect even the smallest irregularity in the functioning of the heart. Smart pacemakers rectify the abnormalities in the heart and re-establish normal body function. It also alerts the patients as well as physicians about the patient's cardiac health. This feature of the smart pacemaker helps to decrease the mortality rate.

North America is expected to hold the largest market share during the forecast period due to initiatives taken by key players, favorable regulations, and advanced technological facilities in the U.S and Canada.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cardioverter Defibrillator Device market

Report ID: SQMIG35A2207

$5,300
BUY NOW GET FREE SAMPLE